Peptides News and Research

RSS

SanMedica’s SeroVital-hgh could revolutionize both anti-aging and weight-loss industries

While the Obesity Society's prestigious 30th Annual Scientific Meeting is the venue for some of the most cutting-edge obesity research in the world, at this year's conference the main highlight wasn't weight loss, but was instead — believe it or not — anti-aging. Research presented by a group of highly renowned scientists revealed an oral compound that experts are predicting could completely revolutionize both the anti-aging and weight-loss industries.

20 Feb 2013

Chiasma, Roche enter agreement to develop and commercialize Octreolin

Roche and Chiasma Inc., a privately held biopharma company, announced today that they have entered into an agreement to develop and commercialize Chiasma's proprietary product Octreolin, initially for acromegaly and subsequently for neuroendocrine tumors.

19 Feb 2013

Researchers explore cellular signals produced by the body in response to traumatic injury

When it comes to healing the terrible wounds of war, success may hinge on the first blood clot - the one that begins forming on the battlefield right after an injury. Researchers exploring the complex stream of cellular signals produced by the body in response to a traumatic injury believe the initial response - formation of a blood clot - may control subsequent healing.

18 Feb 2013

Researchers identify new way to influence the vital serotonin signaling system

An interdisciplinary team of researchers from the University of Texas Medical Branch at Galveston and the University of Houston has found a new way to influence the vital serotonin signaling system - possibly leading to more effective medications with fewer side effects.

14 Feb 2013

GSK1322322 targets gram-positive bacteria including methicillin-resistant strains of MRSA

An increasing number of bacteria is evolving antibiotic resistance. Much-feared representatives of this steadily growing group include Staphylococci strains. At this point, multi-resistant forms of the bacterium Staphylococcus aureus - the "hospital germ" known commonly by its acronym, MRSA - can only be treated with a select subset of antibiotics as many drugs have simply stopped working. This is precisely why the field of medicine is in desperate need of new treatment options.

14 Feb 2013

Study demonstrates how CN2097 works to restore neural functions impaired by Angelman syndrome

In a new study in mice, a scientific collaboration centered at Brown University lays out in unprecedented detail a neurological signaling breakdown in Angelman syndrome, a disorder that affects thousands of children each year, characterized by developmental delay, seizures, and other problems.

14 Feb 2013

New paper advances scientific understanding of glycoproteins’ structure and function

A Simon Fraser University chemist is the lead author on a new paper that advances scientific understanding of the structure and function of glycoproteins, in particular the number and positioning of sugars on them.

14 Feb 2013

Combining synthetic and natural toxins could disarm cancer, drug-resistant bacteria

Cancer researchers from Rice University suggest that a new man-made drug that's already proven effective at killing cancer and drug-resistant bacteria could best deliver its knockout blow when used in combination with drugs made from naturally occurring toxins.

13 Feb 2013

Infusions of regulatory T cells turn off autoimmune attack on joints

Farber Cancer Institute scientists have demonstrated a new strategy for treating autoimmune disease that successfully blocked the development of rheumatoid arthritis in a mouse model. They say it holds promise for improved treatment of arthritis and other autoimmune disorders in people.

10 Feb 2013

Inhibiting JNK enzyme protects against ischemic/reperfusion injury

Using two different compounds they developed, scientists from the Florida campus of The Scripps Research Institute (TSRI) have been able to show in animal models that inhibiting a specific enzyme protects heart cells and surrounding tissue against serious damage from heart attacks.

10 Feb 2013

Tat-beclin 1 shows promise against infections, neurodegenerative disorders and cancer

UT Southwestern Medical Center scientists have synthesized a peptide that shows potential for pharmaceutical development into agents for treating infections, neurodegenerative disorders, and cancer through an ability to induce a cell-recycling process called autophagy.

10 Feb 2013

GLP-1 receptor agonists associated with reduced BMI in adolescents with severe obesity

Preliminary evidence from a clinical trial suggests that treatment with glucagon-like peptide-1 (GLP-1) receptor agonists was associated with reduced body mass index and body weight in adolescents with severe obesity, according to a report published Online First by JAMA Pediatrics, a JAMA Network publication.

5 Feb 2013

Scientists visualise molecular changes in Bax protein that force cells to die

Scientists at the Walter and Eliza Hall Institute have for the first time visualised the molecular changes in a critical cell death protein that force cells to die.

3 Feb 2013

Northeast Ohio Medical University, CEL-SCI produce new investigational breast cancer vaccine

CEL-SCI Corporation announced that its longstanding collaboration with Northeast Ohio Medical University has produced a new investigational breast cancer vaccine which prevents and treats a HER-2/neu expressing breast cancer tumor in a mouse model of the disease.

31 Jan 2013

Finding medical applications for unused inventions: an interview with Gabriel Mecklenburg, Co-Founder of Marblar

Marblar is gamifying the process of technology transfer. We post technology on our platform in the form of a challenge, and the Marblar community then competes to uncover new problems these technologies could solve – thereby discovering new market applications for these technologies.

31 Jan 2013

Foresee, ScinoPharm to form joint venture for new oncological Leuprolide injectable drug

ScinoPharm and Foresee Pharmaceuticals, Inc. jointly announced today that an investment agreement to form a joint venture has been signed. This venture looks to develop a series of peptide injectable drugs with the first being a new oncological Leuprolide injectable drug product, where Leuprolide will be formulated in a proprietary controlled-release drug delivery system originally developed by Foresee and transferred to the joint venture.

30 Jan 2013

OncoPep commences PVX-410 Phase 1/2a trial in smoldering multiple myeloma

OncoPep, Inc. today announced that the Company has initiated a Phase 1/2a clinical trial evaluating PVX-410, a multi-peptide therapeutic cancer vaccine, in patients with smoldering multiple myeloma, an asymptomatic precursor of multiple myeloma, which is an incurable cancer of the plasma cells.

30 Jan 2013

Bone Medical announces initial findings from BN006 proof of concept RA study

Bone Medical Ltd, a biopharmaceutical company focused on the development of new medicines for musculoskeletal diseases, today announced initial findings from a proof of concept study of BN006, a treatment that it is developing for Rheumatoid Arthritis (RA) based on its Mozaic™ peptide discovery technology.

29 Jan 2013

IOF-ESCEO Pre-Clinical Symposium to be held on April 18 in Rome, Italy

Investigators with an interest in pre-clinical and translational musculoskeletal research are invited to attend the 3rd IOF-ESCEO Pre-Clinical Symposium to be held on April 18, in Rome, Italy.

29 Jan 2013

FDA approves Takeda’s NESINA, OSENI and KAZANO for treatment of type 2 diabetes

Takeda Pharmaceutical Company Limited and its wholly-owned subsidiary, Takeda Pharmaceuticals U.S.A., Inc. today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved NESINA (alogliptin) and the fixed-dose combination (FDC) therapies OSENI (alogliptin and pioglitazone) and KAZANO (alogliptin and metformin HCl) for the treatment of type 2 diabetes in adults as adjuncts to diet and exercise.

28 Jan 2013

Peptides News and Research

SanMedica’s SeroVital-hgh could revolutionize both anti-aging and weight-loss industries

Chiasma, Roche enter agreement to develop and commercialize Octreolin

Researchers explore cellular signals produced by the body in response to traumatic injury

Researchers identify new way to influence the vital serotonin signaling system

GSK1322322 targets gram-positive bacteria including methicillin-resistant strains of MRSA

Study demonstrates how CN2097 works to restore neural functions impaired by Angelman syndrome

New paper advances scientific understanding of glycoproteins’ structure and function

Combining synthetic and natural toxins could disarm cancer, drug-resistant bacteria

Infusions of regulatory T cells turn off autoimmune attack on joints

Inhibiting JNK enzyme protects against ischemic/reperfusion injury

Tat-beclin 1 shows promise against infections, neurodegenerative disorders and cancer

GLP-1 receptor agonists associated with reduced BMI in adolescents with severe obesity

Scientists visualise molecular changes in Bax protein that force cells to die

Northeast Ohio Medical University, CEL-SCI produce new investigational breast cancer vaccine

Finding medical applications for unused inventions: an interview with Gabriel Mecklenburg, Co-Founder of Marblar

Foresee, ScinoPharm to form joint venture for new oncological Leuprolide injectable drug

OncoPep commences PVX-410 Phase 1/2a trial in smoldering multiple myeloma

Bone Medical announces initial findings from BN006 proof of concept RA study

IOF-ESCEO Pre-Clinical Symposium to be held on April 18 in Rome, Italy

FDA approves Takeda’s NESINA, OSENI and KAZANO for treatment of type 2 diabetes

Editorial Focus eBook - Peptides and Oligonucleotides (2nd edition) eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News